Literature DB >> 30424704

Bacterial vaginosis: a primer for clinicians.

Suzanne Reiter1, Susan Kellogg Spadt2.   

Abstract

Bacterial vaginosis (BV) affects approximately one third of women in the United States. While often asymptomatic, BV infection may be accompanied by serious health consequences, such as preterm birth and pelvic inflammatory disease, and may facilitate acquisition of sexually transmitted infections. Identifying appropriate patients for screening, such as pregnant women, women planning pregnancy, and women with multiple and/or new sexual partners, is imperative for treatment. Diagnosis of BV has traditionally depended on the presence of vaginal discharge and odor, elevated pH, and clue cells as determined by microscopy, but newer diagnostic modalities that utilize molecular techniques allow for more convenient and accurate testing for BV. Approved treatment options consist of antibiotics administered as oral or intravaginal formulations. Patient counseling and education regarding treatment options, including adherence to prescribed treatments, appropriate hygienic practices, and treatment of symptomatic same-sex partners, are crucial to optimize patient outcomes and prevent recurrence.

Entities:  

Keywords:  Bacterial vaginosis; clindamycin; diagnosis; metronidazole; secnidazole; tinidazole

Mesh:

Substances:

Year:  2018        PMID: 30424704     DOI: 10.1080/00325481.2019.1546534

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  8 in total

1.  Dependence of the dynamics of changes in the quality of life of patients with bacterial vaginosis on local levels of TNF-α and IL-1β.

Authors:  Dmytro Grebeniuk; Oleksandr Nazarchuk; Nataliia Dzis; Illia Taran; Elina Slyvka; Vahif Abdullaiev; Vitalii Bobyr; Oksana Mashevska
Journal:  Acta Biomed       Date:  2022-08-31

2.  Vaginal discharge during pregnancy and associated adverse maternal and perinatal outcomes.

Authors:  Meharunnissa Khaskheli; Shahla Baloch; Aneela Sheeba Baloch; Syed Ghulam Sarwar Shah
Journal:  Pak J Med Sci       Date:  2021 Sep-Oct       Impact factor: 1.088

3.  Exploiting the Anti-Biofilm Effect of the Engineered Phage Endolysin PM-477 to Disrupt In Vitro Single- and Dual-Species Biofilms of Vaginal Pathogens Associated with Bacterial Vaginosis.

Authors:  Joana Castro; Lúcia G V Sousa; Ângela França; Lenka Podpera Tisakova; Lorenzo Corsini; Nuno Cerca
Journal:  Antibiotics (Basel)       Date:  2022-04-22

4.  One-Step Staining Method for the Identification of Clue Cells and Bacterial Morphotypes Associated with Bacterial Vaginosis.

Authors:  Carlos Martínez-Figueroa; Ana Karen Estrada-Moreno; Amalia Vences-Velázquez; Karen Cortés-Sarabia
Journal:  Microbiol Spectr       Date:  2022-05-16

Review 5.  Modifications in Vaginal Microbiota and Their Influence on Drug Release: Challenges and Opportunities.

Authors:  Gerardo Leyva-Gómez; María L Del Prado-Audelo; Silvestre Ortega-Peña; Néstor Mendoza-Muñoz; Zaida Urbán-Morlán; Maykel González-Torres; Manuel González-Del Carmen; Gabriela Figueroa-González; Octavio D Reyes-Hernández; Hernán Cortés
Journal:  Pharmaceutics       Date:  2019-05-06       Impact factor: 6.321

Review 6.  The reproductive tract microbiota in pregnancy.

Authors:  Karen Grewal; David A MacIntyre; Phillip R Bennett
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

7.  N-glycosylation of cervicovaginal fluid reflects microbial community, immune activity, and pregnancy status.

Authors:  Gang Wu; Paola Grassi; David A MacIntyre; Belen Gimeno Molina; Lynne Sykes; Samit Kundu; Cheng-Te Hsiao; Kay-Hooi Khoo; Phillip R Bennett; Anne Dell; Stuart M Haslam
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

8.  Pregnancies after vaginal radical trachelectomy (RT) in patients with early invasive uterine cervical cancer: results from a single institute.

Authors:  Shota Shinkai; Shinichi Ishioka; Tasuku Mariya; Yuya Fujibe; Miseon Kim; Masayuki Someya; Tsuyoshi Saito
Journal:  BMC Pregnancy Childbirth       Date:  2020-04-25       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.